Research Management Group (RMG)

Pfizer Center for Therapeutic Innovation (CTI)-Stanford University
Request for Translational Proposals for Biotherapeutic Targets
Spring 2014 Call for Proposals

**Funding opportunity for Stanford faculty with PI eligibility and CE faculty (with an approved PI waiver).*

CTI is looking for early-stage, large molecule projects related to Inflammation, autoimmunity, tissue remodeling, oncology, rare or genetic diseases, neuroscience, cardiovascular and metabolic diseases.

# of applicants: unlimited numbers of pre-proposals are permitted.

Pre-proposal deadline: Friday, May 23, 2014 (see pre-proposal guidelines below)
Full proposals by invitation only.

Eligibility: faculty with PI eligibility and CE faculty (with an approved CE Faculty PI waiver)

Guidelines: This RFP is not on the sponsor's website.
Download RFP and pre-proposal instructions >> Word

Amount of funding:   amount of funding is determined by the lab and personnel support for duration of time necessary to advance a potential therapeutic to clinical trials. The term is typically 2 to 4 years.

About CTI
CTI: an innovative Pfizer program that partners with leading academic medical centers and foundations nationwide to accelerate the translation of novel targets to the clinic. CTI’s goal is to identify new compounds and accelerate research and drug development from validated target to proof-of-mechanism in the clinic.  A partnership with CTI includes collaborative use of Pfizer’s proprietary antibody drug discovery tools and technologies, broad publishing rights and significant financial awards in the form of milestone and royalty payments for successful programs.

Therapeutic Areas of Interest:

What we look for:

Out of scope:

Biologics for the treatment of rheumatoid arthritis and psoriasis are out of scope for this proposal
As a general rule, CTI is currently unable to accept therapeutics that are small molecule, radiotherapy or vaccines in nature. In addition, there is limited opportunity to pursue HIV targeted therapies within CTI.

Advantages to Collaborating with CTI:

Pre-proposal guidelines:

By Friday, May 23, 2014, please submit one PDF file containing the following in the order listed below to:
Kanad Das
SPARK Program Manager

File name:    Last name_Pfizer_CTI_Spring_2014.pdf

Institutional representatives: you do not have to submit your pre-proposals to your Research Process Manager (RPM). However, if subsequently invited to submit a full proposal, you will need to work with your RPM.

1)  Title page
Name of this RFP:   Stanford University and Pfizer's Center for Therapeutic Intervention Spring 2014 Call for Proposals
Project title:
PI name, title, department, address, email, phone #

2)  2-3 page non-confidential pre-proposal containing:
(this page limit includes references and illustrations)

Project Title
Subject of CTI Research Project

In four sentences or less, please provide a BRIEF statement summarizing of the following:
Overall goal & impact of the mechanism
Desired characteristics
Patient stratification & evidence of PoM

This section should contain:
1) a brief description of the target/pathway and link to human disease and disease mechanism(s). What is/are the unmet medical need(s) this target/pathway could address? Is this pathway targetable with a biotherapeutic?
2) please indicate the novelty/differentiation of this target or approach relevant to disease mechanism (if there are other treatments available, please describe why this is different – greater efficacy/safety etc.)
3) key evidence available to support the hypothesis above (i.e. human genetic, human tissue, preclinical proof of mechanism/concept models)

Please describe any available potential biotherapeutic molecule(s) the PI has generated against the target and its mechanism of action. If available, please describe the characteristic s of said molecule (affinity, humanization, PK etc.) (Please be sure to communicate within limits of any Intellectual Property constraints). If unavailable, please indicate the characteristics of the preferred biotherapeutic agent.

Brief description of potential therapeutic indications expected to be impacted by this mechanism.
Describe the first potential clinical study to demonstrate prood of mechanism including:
1) Patient stratification/selection for the study (i.e. molecular signature, SNP, genetic deficiency etc.)
2) Clinical study endpoints that would allow for testing mechanism in patients.
3) Will this allow for clinical differentiation from other therapies?

Provide a brief description of research plan to be carried out (objectives, specific aims) leading to demonstration of PoM. Please list the available reagents and assays to support research plan. Alternatively, please describe reagents and assays that may need to be developed, and any gaps in the plan (and how Pfizer scientists may contribute, i.e. complete mechanistic studies in vitro, develop cellular assays, discover biomarkers, etc.)

3)  PI biosketch (attachment of an NIH biosketch is acceptable)


Questions? Contact Person
Please contact Kanad Das, SPARK Program Manager, at

Selection process
Stanford University scientists (faculty) whose pre-proposals are selected for further consideration will be invited to submit a full proposal that may be written in collaboration with Pfizer scientists to be evaluated for funding by the CTI-Stanford Steering Committee.

Footer Links: